Ménière's disease is a distinct inner-ear disorder in which tinnitus is one of four symptoms — episodic vertigo, fluctuating hearing loss, tinnitus and ear fullness — so tinnitus without vertigo or fluctuating hearing is unlikely to be Ménière's.
It is not a different name for tinnitus. Understanding the difference matters because Ménière's is diagnosed and treated very differently from tinnitus that occurs on its own.
The four-symptom pattern
Ménière's disease is generally recognized by a specific cluster, not any one symptom in isolation:
- Episodic vertigo — a spinning sensation, often severe, typically lasting 20 minutes to several hours
- Fluctuating hearing loss, usually affecting one ear and often starting with lower-pitched sounds
- Tinnitus, which may become more noticeable just before or during a vertigo episode
- Aural fullness — a feeling of pressure or fullness in the affected ear, similar to the sensation of altitude change
The clinical diagnostic criteria generally require at least two vertigo episodes of 20 minutes or longer, documented hearing loss on at least one occasion, and tinnitus or aural fullness in the affected ear — the combination is what distinguishes it, not any single symptom.
Why it happens
Ménière's is linked to abnormal fluid buildup in the inner ear (endolymphatic hydrops), though what triggers that buildup isn't fully understood. The two are not synonyms, and the difference matters if you have been given one word and not the other: hydrops is a finding in the ear, Ménière's is a syndrome defined by symptoms, and a 2016 review argues the same hydrops also underlies presentations with the hearing symptoms and no vertigo at all. It usually affects one ear, though it can become bilateral over time in a minority of cases, and typically starts between young and middle adulthood.
How it's different from "regular" tinnitus
Tinnitus on its own — without vertigo, fluctuating hearing loss, or aural fullness — is far more common and usually traced to noise exposure, age-related hearing loss, or one of the other causes covered elsewhere on this site. Ménière's is comparatively uncommon — a 2016 review in the Journal of Neurology puts its prevalence at 200 to 500 per 100,000 people — and the vertigo is typically what brings people to a doctor first; tinnitus is often described as a secondary, though still disruptive, part of the picture. If you have tinnitus but have never experienced vertigo or fluctuating hearing, Ménière's is unlikely to be the explanation.
Getting an accurate diagnosis
There's no single definitive test for Ménière's — diagnosis is primarily clinical, based on the symptom pattern, supported by hearing tests and sometimes an MRI to rule out other explanations for similar symptoms, such as vestibular migraine or, less commonly, a vestibular schwannoma (see the article on acoustic neuroma). Because several conditions can mimic Ménière's, including a spinal fluid leak, a formal evaluation by an ENT or neurotologist is worth pursuing rather than assuming based on symptoms alone.
Most of that can proceed at the pace of an ordinary referral. The exception is a sudden drop in hearing in one ear. The US guideline on sudden hearing loss makes it a strong recommendation that clinicians distinguish inner-ear from conductive hearing loss when sudden hearing loss first presents, and emphasises testing hearing as soon as possible and within 14 days of symptoms starting. That applies whether or not Ménière's turns out to be the diagnosis, and sudden sensorineural hearing loss explains why the timing matters.
Managing it
There's no cure, but Ménière's is generally managed rather than left to run its course: a low-sodium diet, diuretics, and vestibular rehabilitation are common first steps, with injections (such as steroids or gentamicin into the middle ear) or surgery reserved for cases that don't respond to more conservative measures. The 2016 review describes the condition itself as bringing a progressive loss of hearing and balance function over time, which is part of why an accurate diagnosis is worth pursuing rather than assuming episodic vertigo will simply resolve on its own.
What happened when Cochrane reviewed all of it at once
In February 2023, Cochrane published a coordinated set of reviews covering essentially every treatment used for Ménière's disease — lifestyle and dietary measures, systemic drugs, intratympanic corticosteroids, intratympanic gentamicin, positive pressure therapy and surgery. Reading them together is more informative than reading any one of them.
They reach the same verdict, over and over: the evidence is very uncertain.
- Systemic drugs — 10 studies, 848 participants. Few trials compare these against placebo or no treatment at all, and what exists is low or very low certainty.
- Intratympanic corticosteroids — 10 studies, 952 participants, all using dexamethasone. Also low to very low certainty.
- Lifestyle and dietary measures — only two randomised trials, one on a specially processed cereal and one on water intake and sleeping in darkness.
Two specific findings deserve pulling out, because they change how the standard advice should be read.
The most commonly recommended dietary measures have never been tested against placebo. Cochrane states it plainly: it did not identify any placebo-controlled randomised trials for interventions frequently recommended to people with Ménière's, such as salt restriction or caffeine restriction. Those are the two things most people with this diagnosis are told to do first, and the trial that would establish whether they work has not been run.
The placebo response is enormous, which explains a lot of the rest. In the intratympanic corticosteroid trials, improvement in vertigo was reported by 96.8% on the steroid and 96.6% on placebo at 6–12 months. When almost everybody improves in both arms, no treatment can separate from the control — and the reviewers flag exactly this as making the results hard to interpret.
Cochrane also raises publication bias directly here, noting two large randomised trials that were identified and remain unpublished.
The other two reviews in the suite land in the same place, and each contributes something the others do not.
Surgery was covered by two trials and 178 participants: one of ventilation tubes against standard treatment, and one comparing endolymphatic sac decompression against sham surgery — a Danish study from the 1980s, and a rare thing to have at all, since operating on people in order to not operate on them is difficult to justify now. The review could find evidence for only two of the five comparisons it set out to make, rated everything low or very low certainty, and notes that many outcomes it planned to assess, including quality of life and adverse effects, were simply not reported.
Positive pressure therapy — the Meniett device — had three trials and 238 participants, all against sham, with follow-up no longer than four months. Pooled, people using it had 0.84 fewer days per month affected by vertigo, with a confidence interval running from 2.12 days fewer to 0.45 days more. An interval that crosses zero includes the possibility of being slightly worse off.
One line from that review is worth keeping for use elsewhere: none of the studies reported how many people had serious adverse events, and the reviewers explicitly decline to guess whether that means none occurred or nobody looked. An absence of reported harm is not evidence of no harm.
One number from the gentamicin review deserves showing, because it makes concrete what "very low certainty" looks like from the inside.
Intratympanic gentamicin was covered by five randomised trials with 137 participants between them. For improvement in vertigo at 6 to 12 months, one of those trials reported 16 of 16 patients improving on gentamicin against 0 of 16 with no intervention — a risk ratio of 33.00, with a 95% confidence interval running from 2.15 to 507.
An interval whose upper bound is 507 is not a measurement. It is what happens when 32 people are split in two and every one of them lands on the same side: the arithmetic still produces a number, and the number means almost nothing. At longer follow-up the same review reports RR 1.63 with an interval of 0.98 to 2.69 — which includes no effect at all.
Neither figure tells you whether gentamicin works. That is the review's own position: more people may report improvement, and the limitations of the evidence mean we cannot be sure.
What to do with this. Not stop treatment — "very uncertain evidence" means the studies cannot tell us, not that the treatments fail. Ménière's is managed by specialists for good reasons and the symptoms are genuinely disabling. What it should change is the confidence with which any particular measure is presented to you, and how quickly you conclude that something is not working. The reviewers' own recurring request is for agreement on what outcomes to measure, so future trials can be compared at all.